MarkSteinMD

Genitourinary Oncology, Hematologic Oncology

Medical Oncologist at Columbia University Medical Center

Overview of Dr. Stein

Dr. Mark Stein is an oncologist in New York, NY and is affiliated with Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center/New York–Presbyterian Hospital. He received his medical degree from New York Medical College and has been in practice 19 years. He is a recognized expert in field of genitourinary oncology – treating patients with prostate, kidney, bladder and testicular cancers. He is also a member of the Experimental Therapeutics program, investigating novel therapies across all solid tumors. In addition to providing standard therapies for the treatment of genitourinary cancers such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator initiated and industry sponsored clinical trials. Dr. Stein has a particular interest in the development of novel immune therapies for cancer

Office
161 Fort Washington Ave
Fl 9
New York, NY 10032
Book by Phone+1(229) 360-6725

Fax+1 212-305-6762

Education & Training

New York Medical CollegeClass of 1998

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2004 - 2025
NY State Medical License 1999 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration Start of enrollment: 2009 Jun 01
Completed
Phase 1, Phase 2
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. Start of enrollment: 2023 Sep 20
TERMINATED
PHASE1, PHASE2
Roles: Contact

Publications & Presentations

PubMed

3 citations
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes.
Nicholas A Zorko, Allison Makovec, Andrew Elliott, Samuel Kellen, John R Lozada
Prostate Cancer and Prostatic Diseases. 2025-03-01
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma.
Miya B Hugaboom, Lena V Wirth, Kelly Street, Neil Ruthen, Opeyemi A Jegede
Cancer Discovery. 2025-02-24
Intratumoral or Subcutaneous MK-2118, a Non-Cyclic Dinucleotide STING Agonist, With or Without Pembrolizumab for Advanced or Metastatic Solid Tumors or Lymphomas.
Jason J Luke, Randy F Sweis, J Randolph Hecht, Reva Schneider, Mark N Stein
Clinical Cancer Research. 2025-01-23

Lectures

Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Study Sheds Light on Diabetes Drug for Prostate CancerNovember 8th, 2023
Common Diabetes Drug Metformin Really Can Fight Certain CancersNovember 10th, 2023
Can Metformin Delay Progression of Prostate Cancer? Study Provides InsightsNovember 11th, 2023